Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma

Abstract excerpt

Background We aimed to characterize serine protease inhibitor Kazal type 1 (SPINK1) as a gene signature for the early diagnosis, molecular targeting, and prediction of immune checkpoint blockade (ICB) treatment response of hepatocellular carcinoma (HCC). Methods The transcriptomics, proteomics, and phenotypic analyses were performed separately or in combination. Results We obtained the following findings on...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Ferroptosis and cancer prognosis
• Share to Hepatocellular Carcinoma Treatment and Prognosis